BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Budigalimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Budigalimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05822752-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Budigalimab: Phase 2 readout est. (NCT05822752)
DESCRIPTION:Budigalimab\, phase 2.\nStudy: Study to Evaluate Adverse Events
 \, and Change in Disease Activity\, When Intravenously (IV) Infused With L
 ivmoniplimab in Combination With IV Infused Budigalimab in Adult Participa
 nts With Hepatocellular Carcinoma (HCC)\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/budigalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5822752
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109272-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06109272)
DESCRIPTION:Budigalimab\, phase 2/3.\nStudy: A Study to Assess the Dose\, A
 dverse Events\, and Change in Disease Activity of Livmoniplimab as an Intr
 avenous (IV) Solution in Combination With Budigalimab as an IV Solution in
  Adult Participants With Hepatocellular Carcinoma (HCC)\nEstimated primary
  completion: January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06109272
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03893955-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Budigalimab: Phase 1 readout est. (NCT03893955)
DESCRIPTION:Budigalimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Determine the Safety\, Tolerability\, Pharmacokinetics\, and Preli
 minary Efficacy of ABBV-927 With ABBV-368\, Budigalimab (ABBV-181) and/or 
 Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03893955
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632951-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Budigalimab: Phase 2 readout est. (NCT06632951)
DESCRIPTION:Budigalimab\, phase 2\, Urothelial Carcinoma.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity When Intravenously 
 (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigali
 mab in Adult Participants With Urothelial Carcinoma (UC)\nEstimated primar
 y completion: March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06632951
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03821935-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Budigalimab: Phase 1 readout est. (NCT03821935)
DESCRIPTION:Budigalimab\, phase 1.\nStudy: Study to Determine the Safety\, 
 Tolerability\, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Liv
 moniplimab (ABBV-151) as a Single Agent and in Combination With Budigalima
 b (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03821935
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05005403-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Budigalimab: Phase 1 readout est. (NCT05005403)
DESCRIPTION:Budigalimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy to Assess Adverse Events and Pharmacokinetics in Adult Participants Wit
 h Non-Small Cell Lung Cancer\, Head and Neck Squamous Cell Carcinoma and O
 ther Solid Tumors\, Receiving Intravenous Infusion of Azirkitug Alone or i
 n Combination(s) With Budigalimab\, Bevacizumab\, or Telisotuzumab Adizute
 can\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05005403
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05599984-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Budigalimab: Phase 1 readout est. (NCT05599984)
DESCRIPTION:Budigalimab\, phase 1.\nStudy: Study to Evaluate Adverse Events
 \, Change in Disease Activity\, and How ABBV-706 Moves Through the Body Wh
 en Intravenously (IV) Infused Alone or in Combination With IV Infused Budi
 galimab\, Cisplatin\, or Carboplatin in Adult Participants With Advanced S
 olid Tumors\nEstimated primary completion: November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05599984
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Budigalimab: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Budigalimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuz
 umab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in 
 Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No 
 Prior Treatment for Advanced Disease\, and No Actionable Genomic Alteratio
 ns\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241039-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Budigalimab: Phase 1 readout est. (NCT07241039)
DESCRIPTION:Budigalimab\, phase 1.\nStudy: A Study to Assess the Adverse Ev
 ents\, Change in Disease Activity\, and How Oral ABBV-711 Tablets Move Thr
 ough the Body as a Monotherapy and in Combination With Intravenously Infus
 ed Budigalimab (ABBV-181)\, in Adults With Advanced Squamous Tumors\nEstim
 ated primary completion: April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07241039
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628310-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Budigalimab: Phase 2 readout est. (NCT06628310)
DESCRIPTION:Budigalimab\, phase 2.\nStudy: A Study to Evaluate the Adverse 
 Events\, Efficacy\, and Optimal Dose of Intravenous (IV) ABBV-400 in Combi
 nation With IV Fluorouracil\, Leucovorin\, and Budigalimab in Adult Partic
 ipants With Locally Advanced Unresectable or Metastatic Gastric\, Gastroes
 ophageal Junction\, or Esophageal Adenocarcinoma\nEstimated primary comple
 tion: October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 udigalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06628310
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06236438-990@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06236438)
DESCRIPTION:Budigalimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events\, Optimal Dose\, and Change in Disease Act
 ivity\, With Livmoniplimab in Combination With Budigalimab Plus Chemothera
 py Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants
  With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: October 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06236438
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
